The Technical Analyst
BioCardia Inc [BCDA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BioCardia Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
2.95% $0.377
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 10.12 mill |
| EPS: | -0.550 |
| P/E: | -0.680 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 26.87 mill |
| Avg Daily Volume: | 0.356 mill |
| RATING 2024-04-26 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.680 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.12x |
| Company: PE -0.680 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.252 (-166.81%) $-0.628 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.348 - 0.406 ( +/- 7.70%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-19 | Frost Phillip Md Et Al | Sell | 129 802 | Common Stock |
| 2023-10-18 | Blank Andrew Scott | Buy | 12 434 | Stock Option (right to buy) |
| 2023-10-18 | Krasno Richard M | Buy | 12 434 | Stock Option (right to buy) |
| 2023-10-18 | Moyes Jay M | Buy | 12 434 | Stock Option (right to buy) |
| 2023-10-18 | Allen Jim L. | Buy | 12 434 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 68.95 |
| Last 98 transactions |
| Buy: 2 428 796 | Sell: 415 660 |
Forecast:
16:00 - $0.373
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.373
Forecast 2: 16:00 - $0.373
Forecast 3: 16:00 - $0.373
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.377 (2.95% ) |
| Volume | 0.0292 mill |
| Avg. Vol. | 0.356 mill |
| % of Avg. Vol | 8.21 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BCDA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $0.400 | N/A | Active |
|---|
BCDA
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Latest Press Releases
2024-04-25 09:00:00 - Press Release
Biocardia Completes Enrollment Of Cardiamp Cell Therapy For The Treatment Of Chronic Myocardial Ischemia Trial Open Label Roll-in Cohort
Call scheduled for study clinical leadership to discuss results and details on pivotal randomized trial call scheduled for study clinical leadership to discuss results and details on pivotal randomized trial
2024-03-27 16:00:00 - Press Release
Biocardia Reports Fourth Quarter And Full Year 2023 Business Highlights And Financial Results
Sunnyvale, calif., march 27, 2024 (globe newswire) -- biocardia®, inc. [nasdaq: bcda], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended december 31, 2023 and filed its annual report on form 10-k with the securities and exchange commission.
2024-03-20 07:00:00 - Press Release
Biocardia To Host 2023 Financial Results And Corporate Update Conference Call On March 27, 2024
Sunnyvale, calif., march 20, 2024 (globe newswire) -- biocardia®, inc. [nasdaq:bcda], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended december 31, 2023 and provide a corporate update by conference call on wednesday, march 27, 2024 at 4:30 pm et.
2024-03-13 07:00:00 - Press Release
Biocardia And Stemcardia Announce Biotherapeutic Delivery Partnership
Biocardia & stemcardia biotechnology company partnership targets heart failure, the leading cause of death and a condition with limited treatment options
2024-03-12 07:00:00 - Press Release
Biocardia Announces Cms Approval Of Coverage For Cardiamp Cell Therapy Confirmatory Phase Iii Heart Failure Study
Centers for medicare & medicaid services (cms) approves reimbursement coverage of the confirmatory phase iii clinical trial of cardiamp heart failure study
Latest News
2024-03-20 07:00:00 - GlobeNewsWire
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
SUNNYVALE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2023 and provide a corporate update by conference call on Wednesday, March 27, 2024 at 4:30 PM ET.
2023-11-15 12:47:47 - Zacks Investment Research
BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study
The FDA approves BioCardia's (BCDA) phase III study on its CardiAMP cell therapy to treat patients with ischemic heart failure.
2023-11-08 20:08:03 - Seeking Alpha
BioCardia, Inc. (BCDA) Q3 2023 Earnings Call Transcript
BioCardia, Inc. (NASDAQ:BCDA ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Miranda Peto - Investor Relations Peter Altman - President and Chief Executive Officer David McClung - Chief Financial Officer Operator Ladies and gentlemen, thank you for standing by and welcome to the BioCardia 2023 Third Quarter Conference Call. At this time, all participants are in a listen-only mode.
2023-11-08 19:32:40 - Zacks Investment Research
BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates
BioCardia, Inc. (BCDA) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.
2023-11-01 17:04:00 - GlobeNewsWire
BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023
SUNNYVALE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2023 by conference call on Wednesday, November 8, 2023 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session.
2023-10-12 12:47:42 - Zacks Investment Research
BioCardia (BCDA) Up on Plans for Second Heart Failure Study
BioCardia (BCDA) completes enrollment in a pivotal phase III study on its CardiAMP cell therapy for the treatment of heart failure. It plans to begin a second study with responders from the initial study.
2023-09-06 12:01:44 - Zacks Investment Research
BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study
Based on one-year follow-up data from a pivotal phase III study, BioCardia (BCDA) reveals that its CardiAMP cell therapy is unlikely to achieve the primary endpoint for the treatment of heart failure.
2023-09-05 09:31:11 - Proactive Investors
BioCardia shares slide on disappointing interim data from heart therapy trial
BioCardia shares fell more than 20% in pre-market trade on Tuesday after the biopharmaceutical firm revealed that its Phase 3 trial of CardiAMP cell therapy for heart failure was unlikely to meet its three-tiered primary efficacy endpoint based on interim trial results. CardiAMP cell therapy uses a patient's own bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body's natural healing response.
2023-08-09 19:44:09 - Zacks Investment Research
BioCardia, Inc. (BCDA) Reports Q2 Loss, Lags Revenue Estimates
BioCardia, Inc. (BCDA) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.14 per share a year ago.
2023-05-23 07:00:00 - GlobeNewsWire
BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study
SUNNYVALE, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announced that the next Data Safety Monitoring Board (DSMB) meeting for the CardiAMP Cell Therapy Trial for Heart Failure is scheduled to take place on July 12th. The Company expects the FDA's response to its adaptive statistical analysis plan supplement early to mid-June and anticipates approval of the plan and completion of all tasks to implement the plan, including all data monitoring, in advance of the DSMB meeting.